Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Circulating tumour DNA (ctDNA) analysis has the potential to improve prognostication, molecular profiling and disease monitoring in patients with cancer. This Review summarizes recent advances, potential applications in cancer research and personalized oncology, and the introduction of ctDNA into clinical use.
This review summarizes the state of the art in chemical probes targeting molecular processes operating at the chromatin interface in cancer cells. It seeks to provide a chemical toolbox for use by scientists to dissect epigenetic vulnerabilities of tumour biology.
In this Review, Nowell and Radtke outline the accumulating evidence that Notch functions as a tumour suppressor in a range of cancers, and present potential mechanisms by which loss of Notch signalling could promote tumorigenesis.
This Opinion article focuses on the trends and progress being made in identifying protein biomarker signatures of clinical utility in cancer using, in particular, blood-based proteomics.
Sumoylation is an important mechanism in cellular responses to stress, and appears to be upregulated in many cancers. This Review argues that sumoylation protects the stability and functionality of otherwise easily misregulated gene expression programmes and signalling pathways of cancer cells.
Proteins regulating cell cycle progression are involved in the formation of most cancer types. This Review discusses the role of cell cycle proteins in cancer, the rationale for targeting them in cancer treatment, results of clinical trials, as well as future therapeutic potential of various cell cycle inhibitors.
This Opinion article discusses progress and challenges in using patient-derived xenograft (PDX) models in cancer precision medicine. It is primarily co-authored by members of the EurOPDX Consortium and as such highlights the merits of shared PDX resources.
In this Review, Dienstmannet al. analyse the complex nature of colorectal cancer and the different subtypes in which this disease can be classified, advocating for a 'multi-molecular' perspective for the development of therapies to treat it.
